Reuters logo
BRIEF-Acorda Therapeutics says expects results from Tozadenant phase 3 clinical trial in Q1 2018​
June 6, 2017 / 10:30 AM / 6 months ago

BRIEF-Acorda Therapeutics says expects results from Tozadenant phase 3 clinical trial in Q1 2018​

June 6 (Reuters) - Acorda Therapeutics Inc

* Acorda Therapeutics Inc - expects results from an ongoing tozadenant phase 3 clinical trial in q1 2018​

* Acorda Therapeutics Inc - ‍ company initiated an open-label, long-term safety study for Tozadenant in Q2 of 2017​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below